CitationShieh, Eugenie; Marzinke, Mark A.; Fuchs, Edward J.; Hamlin, Allyson; Bakshi, Rahul; Aung, Wutyi; Breakey, Jennifer; Poteat, Tonia; Brown, Todd; & Bumpus, Namandjé N., et al. (2019). Transgender Women on Oral HIV Pre-Exposure Prophylaxis Have Significantly Lower Tenofovir and Emtricitabine Concentrations When Also Taking Oestrogen When Compared to Cisgender Men. Journal of the International AIDS Society, 22(11), e25405. PMCID: PMC6832671
AbstractINTRODUCTION: Oral HIV Pre-Exposure Prophylaxis (PrEP) with tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) is highly effective. Transgender women (TGW) have increased HIV risk, but have been underrepresented in trials. For TGW on oestrogens for gender-affirming hormone treatment (GAHT), TDF/FTC-oestrogen interactions may negatively affect HIV prevention or gender-affirming goals. Our aim was to evaluate any pharmacokinetic drug-drug interaction between GAHT and TDF/FTC.
Reference TypeJournal Article
Journal TitleJournal of the International AIDS Society
Marzinke, Mark A.
Fuchs, Edward J.
Bumpus, Namandjé N.
Hendrix, Craig W.